By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ACADIA Pharmaceuticals, Inc. 

3911 Sorrento Valley Boulevard

San Diego  California  92121   U.S.A.
Phone: 858-558-2871 Fax: 858-558-2872


ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.


July 16, 1993


Founder: Mark Brann

CEO: Stephen Davis

CMO (Medical): Randall Owen


Please click here for Acadia Pharma job opportunities.


Please click here for clinical trial information.


All Products

Key Statistics

Ownership: Public

Web Site: Acadia
Employees: 140
Symbol: ACAD

Drug Discovery


Allergan  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Allergan  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Allergan  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.

Sunovion  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.

Company News
Acadia (ACAD) Announces Appointment Of Michael J. Yang As Executive Vice President, Chief Commercial Officer 3/30/2017 8:27:30 AM
Acadia (ACAD) Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2016 3/1/2017 6:56:55 AM
Acadia (ACAD) To Announce Fourth Quarter And Full Year 2016 Financial Results On February 28, 2017 2/21/2017 8:17:23 AM
Always a Bridesmaid, Never a Bride: Acadia (ACAD) Moves Higher on Takeover Speculation 2/6/2017 6:05:59 AM
Acadia (ACAD) Stock Screams Upward; Primary Endpoint Met in Phase II Study of Pimavanserin for Alzheimer’s 12/20/2016 7:07:39 AM
Acadia (ACAD) Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder 12/1/2016 7:59:07 AM
Acadia (ACAD) Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia 11/15/2016 11:08:33 AM
Acadia (ACAD) Reports Third Quarter 2016 Financial Results 11/8/2016 10:44:17 AM
Acadia (ACAD) Initiates Phase III Trial Of Pimavanserin For Adjunctive Treatment In Patients With Schizophrenia 11/3/2016 11:30:59 AM
Acadia (ACAD) To Announce Third Quarter 2016 Financial Results On November 7, 2016 11/1/2016 11:45:18 AM